Syneos Health to Present at the 40th Annual J.P. Morgan Healthcare Conference
MORRISVILLE, N.C., Jan. 04, 2022 - Syneos Health (Nasdaq:SYNH) announced that CEO Alistair Macdonald will present at the 40th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MORRISVILLE, N.C., Jan. 04, 2022 - Syneos Health (Nasdaq:SYNH) announced that CEO Alistair Macdonald will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 10:30 a.m. EST. A webcast, presentation materials, and an archived audio replay will be available on the Company’s Investor Relations website.
Syneos Health is a fully integrated biopharmaceutical solutions organization, employing approximately 28,000 people across over 110 countries to expedite the delivery of therapies.
Details
News Market Reaction – SYNH
The recorded move for SYNH in the trading session of this news was -5.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, today announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 10:30 a.m. EST.
A webcast of the event, along with a link to the presentation materials and archived audio replay of the presentation, will be available on the Company’s Investor Relations website at investor.syneoshealth.com.
About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically integrating clinical development, medical affairs and commercial capabilities to address modern market realities.
We bring together approximately 28,000 minds, across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.
| Investor Relations Contact: | Press/Media Contact: |
| Ronnie Speight | Gary Gatyas |
| Senior Vice President, Investor Relations | Executive Director, External Communications |
| +1 919 745 2745 | +1 908 763 3428 |
| Investor.Relations@syneoshealth.com | gary.gatyas@syneoshealth.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.